A Multicenter, Randomized, Open-label, Active-controlled, Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine Versus Nab-paclitaxel Plus Gemcitabine as the First-line Treatment in Metastatic Pancreatic Cancer
Latest Information Update: 26 Mar 2025
At a glance
- Drugs Camrelizumab (Primary) ; Gemcitabine (Primary) ; Paclitaxel (Primary) ; Surufatinib (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- Sponsors HUTCHMED
Most Recent Events
- 19 Mar 2025 According to a HUTCHMED media release, Completed enrollment of Phase II part of study.
- 24 Jun 2024 According to a HUTCHMED media release, company will host R&D update in Shanghai, China, and via webcast on Tuesday, July 9, 2024 to provide updates on certain programs within HUTCHMED's extensive and innovative pipeline. This will include updates on the Phase III ESLIM-01 and Phase II/III ESLIM-02 studies he surufatinib Phase II/III study for metastatic pancreatic ductal adenocarcinoma, and the Phase III RAPHAEL study of our IDH1/2 inhibitor HMPL-306 in acute myeloid leukemia.
- 14 May 2024 According to a HUTCHMED media release, After an initial safety run-in stage, the Phase II/III stage of the study may enroll a further 500 patients, with a primary endpoint of overall survival (OS).